Related Experiment Video
Updated: Jul 19, 2025

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Engagement with the HCV care cascade among high-risk groups: A population-based study
Aysegul Erman1,2, Karl Everett2, William W L Wong1,2,3
1Toronto Health Economics and Technology Assessment Collaborative (THETA), University Health Network, Toronto, ON, Canada.
Hepatitis C virus (HCV) elimination in Ontario faces challenges, with treatment initiation being a key gap. Improving HCV screening and linkage to care for at-risk populations is crucial for equitable outcomes.
Area of Science:
- Hepatology and Viral Hepatitis Research
- Public Health and Epidemiology
- Health Services Research
Background:
- Understanding the Hepatitis C Virus (HCV) care cascade is essential for elimination strategies.
- A comprehensive description of the HCV care cascade in the direct-acting antiviral (DAA) era has not been previously documented for Ontario, Canada.
- Key at-risk populations, including baby boomers, immigrants, and individuals experiencing residential instability, require specific attention within the HCV care cascade.
Purpose of the Study:
- To describe the population-level HCV care cascade in Ontario, Canada.
- To stratify the HCV care cascade by key risk groups: baby boomers, immigrants, and individuals experiencing residential instability.
- To identify demographic and socioeconomic predictors of engagement with different stages of HCV care.
Main Methods:
- A population-based cohort study was conducted using HCV testing data from Ontario residents between January 1, 1999, and December 31, 2018.
- The HCV care cascade, including antibody diagnosis, RNA testing, genotyping, treatment initiation, sustained virologic response, and reinfection/relapse, was mapped.
- Cause-specific hazard modeling was employed to determine predictors of engagement across the HCV care continuum.
Main Results:
- Among 108,428 individuals with an HCV antibody diagnosis, 88% received RNA testing, 62% tested RNA positive, and 94% of those were genotyped.
- Only 53% of individuals with confirmed viremia initiated treatment, with 76% achieving sustained virologic response; approximately 1% experienced reinfection or relapse.
- Lower engagement rates across the HCV care cascade were observed in males, older cohorts, long-term residents, individuals with substance use disorder or social marginalization, and those diagnosed pre-DAA era.
Conclusions:
- Despite advancements in the DAA era, a significant gap remains in HCV treatment initiation.
- Enhanced HCV screening and improved linkage-to-treatment strategies are necessary, particularly for individuals with a history of substance use disorder and social marginalization.
- Equitable closure of HCV care gaps in Ontario necessitates targeted interventions for vulnerable populations.
Related Concept Videos
Retrovirus Life Cycles
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Chronic Kidney Disease III: Interprofessional Care
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Preventive Healthcare Services

